Swipe om te navigeren naar een ander artikel
The purpose of the study is to assess longitudinal changes in general and disease-specific health-related quality-of-life (HRQOL) indices after intensity-modulated radiotherapy (IMRT) monotherapy for patients with localized prostate cancer (PCA).
Between 2006 and 2010, 91 patients with localized PCA underwent IMRT monotherapy and were enrolled into this prospective study. At baseline, and at 3, 6, 12, and 24 months after IMRT, the general and prostate-specific HRQOL were estimated using physical (PCS) and mental component summaries (MCS) calculated using the Medical Outcomes Study 8-Item Short Form Health Survey and Expanded Prostate Cancer Index Composite (EPIC).
For 2 years, there were no significant changes in EPIC scores in all subscales of urinary domain, hormonal function, and bother. Bowel and sexual function scores decreased after IMRT and did not return to those at baseline (p = 0.006 and < 0.001, respectively). PCS began to decrease at 3 months after IMRT and then returned to the baseline score at 24 months. In contrast, the MCS score began to significantly increase after IMRT, and thereafter the score remained constant until 24 months (p < 0.001). On multivariate logistic regression analysis, urinary (p = 0.003) and sexual functions (p = 0.0005) at baseline were identified as significant predictors of EPIC urinary irritative/obstructive score and sexual function at 24 months after IMRT.
Urinary function, including irritative/obstruction symptoms and hormonal function, was not affected by IMRT. However, bowel and sexual function decreased after IMRT. These findings will provide important information for PCA patients considering IMRT.
Shinohara, N., Maruyama, S., Shimizu, S., Nishioka, K., Abe, T., C-Hatanaka, K., et al. (2013). Longitudinal comparison of quality of life real-time tumor-tracking intensity-modulated radiation therapy and radical prostatectomy in patients with localized prostate cancer. Journal of Radiation Research. doi: 10.1093/jrr/rrt049.
Zelefsky, M. J., Fuks, Z., Hunt, M., Yamada, Y., Marion, C., Ling, C. C., et al. (2002). High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. International Journal of Radiation Oncology Biology Physics, 53(5), 1111–1116. CrossRef
Manger, S. A., Huddart, R. A., Parker, C. C., Dearnaley, D. P., Khoo, V. S., Horwich, A., et al. (2005). Technological advances in radiotherapy for the treatment of localized prostate cancer. European Journal of Cancer, 41(6), 908–921. CrossRef
Lips, I., Dehnad, H., Kruger, A. B., van Moorselaar, J., van der Heide, U., Battermann, J., et al. (2007). Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity- modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. International Journal of Radiation Oncology Biology Physics, 69(3), 656–661. CrossRef
Quon, H., Cheung, P. C., Loblaw, D. A., Morton, G., Pang, G., Szumacher, E., et al. (2012). Quality of life after hypofractionated concomitant intensity-modulated radiation therapy boost for high-risk prostate cancer. International Journal of Radiation Oncology Biology Physics, 83(2), 617–623.
Brassell, S. A., Elsamanoudi, S. I., Cullen, J., Williams, M. E., Mcleod, D. G. (2013). Health-related quality of life for men with prostate cancer-an evaluation of outcomes 12–24 months after treatment. Urologic Oncology: Seminars and Original Investigations, 31(8), 1504–1510.
Sheets, N. C., Goldin, G. H., Meyer, A. M., Wu, Y., Chang, Y., Sturmer, T., et al. (2012). Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA, the Journal of the American Medical Association, 307(15), 1611–1620. CrossRef
Kakehi, Y., Takegami, M., Suzukamo, Y., Namiki, S., Arai, Y., Kamoto, T., et al. (2007). Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite. Journal of Urology, 177(5), 1856–1861. PubMedCrossRef
Homma, Y., Tsukamoto, T., Yasuda, K., Ozono, S., Yoshida, M., & Shinji, M. (2002). Linguistic validation of Japanese version of international prostate symptom score and BPH impact index. The Japanese Journal of Urology (Japanese), 93(6), 669–680.
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable university of half a standard deviation. Medical Care, 41(5), 582–592. PubMed
Mohler, J. L., Armstrong, A. J., Bahnson, R. R., Cohen, M., D’Amico, A. V., Eastham, J. A., et al. (2013). NCCN clinical practice guideline in Oncology-prostate cancer. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 5 Feb 2013.
Morton, G. C., Loblaw, A., Chung, H., Tsang, G., Sankreacha, R., Deabreu, A., et al. (2011). Health-related quality of life after single-fraction high-dose-rate brachttherapy and hypofractionated external beam radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics, 80(5), 1299–1305. CrossRef
- Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer
- Springer International Publishing